| SOLOIST-WHF and SCORED explored the effects of sotagliflozin on cardiorenal outcomes. |
| The results reconfirm the class effects of SGLT2i but also differentiate sotagliflozin from other agents. |
| Dual SGLT inhibition might contribute to the unique safety and efficacy profile of the drug. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.